About Modifi Bio
Modifi Bio is a company based in New Haven (United States) founded in 2021 by Ranjit Bindra and Kingson Lin was acquired by Merck in October 2024. Modifi Bio has raised $11.7 million across 3 funding rounds from investors including Merck, BrightEdge and Yale University. Modifi Bio operates in a competitive market with competitors including Biodexa Pharmaceuticals, OncoSynergy, Plex Pharmaceuticals, Flag Therapeutics and Purposeful, among others.
- Headquarter New Haven, United States
- Founders Ranjit Bindra, Kingson Lin
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Modifi Biosciences, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Modifi Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Modifi Bio
Modifi Bio has successfully raised a total of $11.7M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $995.5 thousand completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Modifi Bio
Modifi Bio has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, BrightEdge and Yale University.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science companies are targeted for private equity investments.
|
Locked | Locked | Locked | |
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Locked | Locked | Locked | |
|
Private equity and debt investments are focused on multiple sectors.
|
Locked | Locked | Locked |
Investor details for Modifi Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Modifi Bio
Investment portfolio details for Modifi Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Modifi Bio
Detailed financials for Modifi Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Modifi Bio Comparisons
Peer comparison for Modifi Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Modifi Bio
Modifi Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biodexa Pharmaceuticals, OncoSynergy, Plex Pharmaceuticals, Flag Therapeutics and Purposeful, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for aggressive rare brain cancers are developed.
|
|
| Locked | Locked | Locked |
Resistance mechanism inhibitors for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Discovering small molecules for diseases caused by protein misfolding such as Parkinson's.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for difficult-to-treat cancers are developed.
|
|
| Locked | Locked | Locked |
Purposeful is engaged in discovering treatments for rare diseases.
|
Detailed competitors of Modifi Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Modifi Bio
Complete news archive for Modifi Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Modifi Bio
Modifi Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Modifi Bio is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Modifi Bio is a funded company, having raised a total of $11.7M across 3 funding rounds to date.
Developer of therapeutics for the treatment of cancer. The company focuses on developing therapeutics that uniquely target specific acquired cancer cell DNA mutations for the treatment of all cancer types.
Modifi Bio's top competitors include Diakonos, Biodexa Pharmaceuticals and OncoSynergy.
Modifi Bio has 9 investors. Key investors include Merck, BrightEdge, Yale University, HighCape Capital, and The Sontag Foundation.